Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Oct 21;13(39):5267-72.
doi: 10.3748/wjg.v13.i39.5267.

Serum transforming growth factor-beta1 level reflects disease status in patients with esophageal carcinoma after radiotherapy

Su-Ping Sun  1 , Ye-Ning Jin, Hong-Peng Yang, Yi Wei, Zhao Dong
Affiliations

Serum transforming growth factor-beta1 level reflects disease status in patients with esophageal carcinoma after radiotherapy

Su-Ping Sun et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the relationship between changes in serum transforming growth factor beta1 (TGFbeta1) level and curative effect of radiotherapy (RT) in patients with esophageal carcinoma.

Methods: Ninety patients with histologically confirmed esophageal carcinoma were enrolled. Serum samples for TGFbeta1 analysis were obtained before and at the end of RT. An enzyme-linked immunosorbent assay was used to measure serum TGFbeta1 level. Multivariate analysis was performed to investigate the relationship between disease status and changes in serum TGFbeta1 level.

Results: Serum TGFbeta1 level in patients with esophageal carcinoma before RT was significantly higher than that in healthy controls (P < 0.001). At the end of RT, serum TGFbeta1 level was decreased in 67.82% (59/87) of the patients. The overall survival rate at 1, 3 and 5 years was 48.28% (42/87), 19.54% (17/87) and 12.64% (11/87), respectively. Main causes of death were local failure and regional lymph node metastasis. In patients whose serum TGFbeta1 level decreased after RT, the survival rate at 1, 3 and 5 years was 61.02% (36/59), 28.81% (17/59) and 18.64% (11/59), respectively. The survival rate at 1 year was 17.86% (5/28) in patients whose serum TGFbeta1 level increased after RT, and all died within 18 mo (P < 0.01).

Conclusion: Serum TGFbeta1 level may be a useful marker for monitoring disease status after RT in patients with esophageal carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival status of all patients, and those with decreased and increased serum TGFβ1 levels. These data show statistically significant differences in the increased group compared with the decreased group and all patients (P < 0.01). Solid line indicates the decreased group; broken line indicates all patients; and dashed line indicates the increased group.
See this image and copyright information in PMC

References

    1. Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A, Sakamoto K. Low-dose rate telecobalt therapy as a boost against esophageal carcinomas. Cancer. 1992;69:1099–1103. - PubMed
    1. Smalley SR, Gunderson LL, Reddy EK, Williamson S. Radiotherapy alone in esophageal carcinoma: current management and future directions of adjuvant, curative and palliative approaches. Semin Oncol. 1994;21:467–473. - PubMed
    1. Wang Y, Shi XH, He SQ, Yao WQ, Wang Y, Guo XM, Wu GD, Zhu LX, Liu TF. Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:131–136. - PubMed
    1. Gao XS, Qiao XY, Yang XR, Asaumi J, Zhou ZG, Wang YD, Zhou DA, Wan J, Kuroda M, Kishi K, et al. Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. Oncol Rep. 2002;9:767–772. - PubMed
    1. Zhao KL, Wang Y, Shi XH. Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma. World J Gastroenterol. 2003;9:1374–1376. - PMC - PubMed

MeSH terms

Substances